As well as working with our clients, Mycosynthetix has in-house discovery projects addressing cancer and neglected diseases; these are summarized in the table below together with our fungal product out-licensing opportunities. Please contact Dr. Cedric Pearce at cpearce@.mycosynthetix.com for additional details.
|Application||Target||Status January 2012|
The development of mevalocidin for organic farming. The optimization is being funded through a Phase 1 SBIR award from the USDA-NIFA program.
|Herbicide||Novel herbicide identified and patented (by Dow AgroSciences LLC – see elsewhere on this site) now under development in our laboratories.|
Collaboration with Professor N. Oberlies of the the University of North Carolina Greensboro and funded by a Program Grant from the National Cancer Institute (PO1-CA125066) through The Ohio State University (Professor Douglas Kinghorn).
|Cytotoxicity, various cells||Novel active compounds identified and evaluated in the NCI 60 cell line panel. Provisional patents being filed. Other lead fungi being analyzed and evaluated.|
Collaboration with Professor Scott Franzblau of the Institute for Tuberculosis Research, University of Illinois – Chicago.
|Tuberculosis||Active fungi being evaluated and prioritized.|
Collaboration with Professors B. Baker and D. Kyle of the University of South Florida to discover new malaria medicines.
Collaboration with Professor A.Satoskar, OSU to discover endophytic fungi which produce anti-leishmania compounds.
|Malaria, Leishmaniasis||Screening and evaluation of active fungi on-going. Leishmaniasis research funded through the NIH.|